Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable condition that predisposes affected individuals to ventricular arrhythmia and sudden cardiac death (SCD). Through genomic screening, it may be possible to identify at-risk individuals and family members prior to the onset of any symptoms, thereby reducing the morbidity and mortality associated with ARVC. However, several unknowns remain that limit the application of this precision medicine approach, including genotype prevalence in a general population, disease penetrance and its modifiers, and the phenotypic characteristics associated with incidentally identified, ARVC-associated genetic variants. In this talk, Interfaces alumnus Dr. Eric Carruth discusses the research being done through Geisinger’s MyCode Community Health Initiative to answer these pressing questions and pioneer a genome-first approach to ARVC identification and diagnosis. The video of this presentation is available here.